Skip to main content

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.

Publication ,  Journal Article
Halabi, S; Carthon, BC; Kelly, WK
Published in: JAMA Oncol
August 1, 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Oncol

DOI

EISSN

2374-2445

Publication Date

August 1, 2022

Volume

8

Issue

8

Start / End Page

1137 / 1138

Location

United States

Related Subject Headings

  • Risk
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Male
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Carthon, B. C., & Kelly, W. K. (2022). To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence. JAMA Oncol, 8(8), 1137–1138. https://doi.org/10.1001/jamaoncol.2022.1623
Halabi, Susan, Bradley C. Carthon, and Wm Kevin Kelly. “To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.JAMA Oncol 8, no. 8 (August 1, 2022): 1137–38. https://doi.org/10.1001/jamaoncol.2022.1623.
Halabi S, Carthon BC, Kelly WK. To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence. JAMA Oncol. 2022 Aug 1;8(8):1137–8.
Halabi, Susan, et al. “To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.JAMA Oncol, vol. 8, no. 8, Aug. 2022, pp. 1137–38. Pubmed, doi:10.1001/jamaoncol.2022.1623.
Halabi S, Carthon BC, Kelly WK. To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence. JAMA Oncol. 2022 Aug 1;8(8):1137–1138.

Published In

JAMA Oncol

DOI

EISSN

2374-2445

Publication Date

August 1, 2022

Volume

8

Issue

8

Start / End Page

1137 / 1138

Location

United States

Related Subject Headings

  • Risk
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Male
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis